background: the her-2/neu gene is located on chromosome 17q21 and encodes a 185-kda transmembrane glycoprotein with tyrosine kinase activity reported to be released in soluble form in various malignancies. objective: to evaluate the clinical significance of soluble her-2/neu as a diagnostic marker in lung cancer. methods: serum levels of soluble her-2/neu were measured in 43 patients with lung ...

The developmental expression of immunocytochemical reactivity to 3 monoclonal antibodies (Mabs Neu 4, Neu 5, and Neu 9) that were generated against adult rat olfactory epithelium was examined in olfactory tissues of embryonic rats. Tissues examined included the nasal olfactory epithelium, nerve, and olfactory bulb, as well as vomeronasal epithelium and nerve. Reactivity patterns of these Mabs i...

BACKGROUND Serum HER-2/neu antigen concentrations have been reported to correlate with increased tumor volume in patients with breast cancer. We measured serum CA 15-3, a surrogate marker of disease burden, and correlated serum CA 15-3 with serum HER-2/neu and analyzed the association of both markers with clinical outcomes. METHODS Pretreatment serum samples from 566 patients were retrospecti...

PURPOSE To evaluate the safety of an HER-2/neu intracellular domain (ICD) protein vaccine and to estimate whether vaccine dose impacts immunogenicity. PATIENTS AND METHODS Twenty-nine patients with HER-2/neu-overexpressing breast or ovarian cancer and with no evidence of disease after standard therapy received a low- (25 microg), intermediate- (150 microg), or high-dose (900 microg) HER-2/neu...

The HER-2/neu gene product, p185(neu), is a membrane-bound receptor with tyrosine kinase activity. High levels of p185(neu) is correlated with intrinsic chemoresistance of non-small cell lung cancer (NSCLC) cell lines. We investigated the effects of tyrphostin AG825, a selective tyrosine kinase inhibitor preferentially inhibiting HER-2/neu kinase, on the chemosensitivities and on the drug-induc...

Every day the global media system produces an abundance of news stories, all containing many references to people. An important task is to automatically generate reliable lists of people by analysing news content. We describe a system that leverages large amounts of data for this purpose. Lack of structure in this data gives rise to a large number of ways to refer to any particular person. Enti...

http://bmj.com/cgi/content/full/328/7430/30 Updated information and services can be found at: These include: Data supplement http://bmj.com/cgi/content/full/328/7430/30/DC1 "Additional references" References http://bmj.com/cgi/content/full/328/7430/30#otherarticles 13 online articles that cite this article can be accessed at: http://bmj.com/cgi/content/full/328/7430/30#BIBL This article cites 2...

HER-2/neu is a self-antigen expressed by tumors and nonmalignant epithelial tissues. The possibility of self-tolerance to HER-2/neu-derived epitopes has raised questions concerning their utility in antitumor immunotherapy. Altered HER-2/neu peptide ligands capable of eliciting enhanced immunity to tumor-associated HER-2/neu epitopes may circumvent this problem. The human CTL peptide HER-2/neu (...

OBJECTIVES To detect amplification of the HER2/neu gene by means of fluorescence in situ hybridization (FISH) in a series of 13 salivary duct carcinomas (SDCs) and to compare the results with immunohistochemical (IHC) assessment of HER2/neu protein expression. DESIGN Retrospective analysis. SETTING Department of Pathology, University of Brescia. PATIENTS We studied 13 cases of SDC diagnos...

PURPOSE The purpose of this study was to immunize patients with HER-2/neu-overexpressing cancer with a multipeptide vaccine comprised of four class II HER-2/neu peptides that had been identified as the most immunogenic in a previous clinical trial. Furthermore, we questioned whether MHC binding affinity could predict the in vivo immunogenicity of the HER-2/neu helper peptides. EXPERIMENTAL DE...